|
|
 |
|
Viewing report
|
|
|
|
The Outlook for Pharmaceuticals in Central & Eastern Europe to 2013
Espicom Business Intelligence Ltd, March 2008
The countries of Central and Eastern Europe represent a total market of 285 million people and a combined GDP of US$3.0 trillion in 2008
The impact of EU accession on the pharmaceutical market
In May 2004, five of the CEE markets in question joined the European Union. Much of the pharmaceutical legislation within the region has therefore been harmonised with that of the EU, although countries such as Poland are still in the process of transposing EU directives into national law.
Romania and Bulgaria have also amended the relevant legislation and became full EU members in January 2007. The implementation of GMP is also taking place across most of the region and this will inevitably improve the quality of overall production and lead to a rise in market values.
Variations in the quality of IP protection
The level of IP protection offered by the CEE nations varies across the region, but the issue generally remains an international concern. Problems that are commonly raised include a lack of transparency in IP procedures and the lack of effective enforcement. Some countries, such as Bulgaria, have made a lot of progress in improving the legal climate by strengthening patent laws and extending the standard patent term to 20 years.
The dominance of the generics market
The demand for affordable drugs is the principal factor in the dominance of the generics in the region. Despite recent improvements in patent protection, legislation and effective enforcement are still needed in many countries where counterfeiting of Western drugs continues. Generics production has managed to remain strong in countries that are also home to the producers of branded drugs. In the former Czechoslovakia for example, the merger of Leciva with Slovakofarma enhanced generics production in 2003. However, as economies develop the trend to importing higher value branded products can be seen.
These reports analyse the issues which matter
Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include 4 completely updated reports sent quarterly, plus a comprehensive report sent annually. There are over 65 markets covered in the worldwide series.
11 Major Markets Covered!
- Bulgaria
- Hungary
- Russia
- Slovenia
- Croatia
- Poland
- Serbia
- Ukraine
- Czech Republic
- Romania
- Slovakia
Customers who bought this item also bought
Oil and Gas in Central Asia and Northwest China
Gedeon Richter Generics Company Intelligence Report
The Burgeoning Battle For Travelers To Central And Eastern Europe: As U.S. Airlines Set Their Sights On International Routes, How Will The Contenders Respond?
U.S. Central Station Patient Monitoring Market
Top 200 Banks in Central and Eastern Europe
The Pharmaceutical Market: Hungary
Central American Country Outlook Package
Indian Pharmaceutical Industry: The Changing Prescription
|
|
|
|
